News & Updates
Filter by Specialty:
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
16 Feb 2023
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
11 Feb 2023
Herbal combo regimen shows promise for ulcerative colitis
A combination regimen comprising two herbal extracts – curcumin and Qing Dai (QD) – have shown potential in the treatment of active* ulcerative colitis (UC), according to two trials from Israel presented at Crohn’s & Colitis Congress (CCC) 2023.
Herbal combo regimen shows promise for ulcerative colitis
10 Feb 2023
Alcohol drinking blamed for rise in colorectal cancer cases among young adults
Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.
